abstract |
A compound represented by formula (1-1) or (1-2), or a pharmacologically acceptable salt thereof retains a principal therapeutic effect of sitaxentan and has an improved CYP inhibitory effect. (see formula 1-1) or (see formula 1-2) wherein R1 is a halogen atom, etc., R2 is a methyl group, etc., R3 is a C1-6 alkyl group, etc., and M is a group represented by: (see above formula), etc. |